tiprankstipranks
vTv Therapeutics (VTVT)
NASDAQ:VTVT

vTv Therapeutics (VTVT) AI Stock Analysis

Compare
762 Followers

Top Page

VT

vTv Therapeutics

(NASDAQ:VTVT)

33Underperform
vTv Therapeutics is currently facing significant financial difficulties, with negative cash flows and a weak balance sheet. Technical analysis suggests a bearish trend, and the valuation is unattractive with a negative P/E ratio. While there are potential opportunities in new product developments, risks remain due to recent partnership terminations. Overall, the stock presents a high-risk investment profile typical of early-stage biotech companies.

vTv Therapeutics (VTVT) vs. S&P 500 (SPY)

vTv Therapeutics Business Overview & Revenue Model

Company DescriptionvTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of orally administered small molecule drug candidates. The company is dedicated to addressing the unmet medical needs in various therapeutic areas including diabetes, autoimmunity, and inflammatory disorders. Their innovative approach leverages a proprietary drug discovery platform to advance their pipeline of potential treatments.
How the Company Makes MoneyvTv Therapeutics primarily generates revenue through partnerships and collaborations with larger pharmaceutical companies. These collaborations often involve upfront payments, milestone payments upon achieving certain development or regulatory goals, and potential royalties on sales if the drug candidates reach the market. Additionally, the company may receive funding through grants and research agreements that support their clinical trials and drug development efforts. However, as a clinical-stage company, vTv Therapeutics does not yet have any products on the market, which means its primary revenue sources are its partnerships and any associated licensing agreements.

vTv Therapeutics Financial Statement Overview

Summary
vTv Therapeutics faces substantial financial challenges, with negative profitability and cash flows, compounded by a weak balance sheet. The company remains heavily reliant on external financing to fund its operations, reflecting a high-risk profile typical of early-stage biotechnology firms. Prospects for improvement hinge on achieving sustained revenue growth and margin improvements.
Income Statement
12
Very Negative
The income statement reveals significant challenges for vTv Therapeutics, characterized by consistently negative net income and EBIT margins. The company shows a net loss of $18.3 million for the TTM period, with an EBIT margin of -2420%. Revenue growth remains volatile, with TTM revenues of $991,000 compared to $0 in the previous annual period. However, this improvement is from a low base and does not indicate consistent growth.
Balance Sheet
25
Negative
The balance sheet depicts a precarious financial position, with high leverage and limited equity. The debt-to-equity ratio is concerning due to negative equity, although total debt is relatively low at $213,000. The company has a positive cash position with cash and equivalents exceeding total debt, but the overall equity remains negative.
Cash Flow
30
Negative
Cash flow analysis shows negative operating and free cash flows, with a significant reliance on financing activities to sustain operations. The TTM free cash flow is -$23.4 million, and the operating cash flow is also negative at -$23.4 million. The company's ability to convert net income into cash flow is constrained, limiting operational flexibility.
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
991.00K0.002.02M4.00M6.41M2.76M
Gross Profit
923.00K-13.60M1.93M3.92M-4.60M-12.36M
EBIT
-24.00M-25.50M-22.54M-21.66M-11.85M-20.89M
EBITDA
-22.22M-25.41M-24.77M-17.52M-12.02M-19.97M
Net Income Common Stockholders
-18.31M-20.25M-25.07M-17.73M-8.83M-21.94M
Balance SheetCash, Cash Equivalents and Short-Term Investments
1.68M9.45M12.13M13.41M5.75M1.78M
Total Assets
8.56M11.02M33.24M25.47M14.79M9.27M
Total Debt
15.71M529.00K716.00K932.00K915.00K7.11M
Net Debt
14.03M-8.92M-11.41M-12.48M-4.83M5.34M
Total Liabilities
91.41M29.57M43.98M35.21M94.89M58.29M
Stockholders Equity
-82.85M-24.68M-10.74M-9.74M-80.10M-49.02M
Cash FlowFree Cash Flow
-23.40M-19.08M-16.04M-19.31M-18.00M-23.09M
Operating Cash Flow
-23.40M-19.08M-16.02M-19.31M-18.00M-23.02M
Investing Cash Flow
4.40M4.40M-21.00K0.000.00242.00K
Financing Cash Flow
52.33M12.00M14.75M26.98M19.47M22.87M

vTv Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price14.56
Price Trends
50DMA
16.30
Negative
100DMA
15.65
Negative
200DMA
16.40
Negative
Market Momentum
MACD
-0.62
Positive
RSI
36.53
Neutral
STOCH
3.69
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTVT, the sentiment is Negative. The current price of 14.56 is below the 20-day moving average (MA) of 18.19, below the 50-day MA of 16.30, and below the 200-day MA of 16.40, indicating a bearish trend. The MACD of -0.62 indicates Positive momentum. The RSI at 36.53 is Neutral, neither overbought nor oversold. The STOCH value of 3.69 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VTVT.

vTv Therapeutics Risk Analysis

vTv Therapeutics disclosed 62 risk factors in its most recent earnings report. vTv Therapeutics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

vTv Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
$5.80B44.4823.55%39.94%32.10%
66
Neutral
$703.51M222.83%23.89%16.86%
51
Neutral
$5.83B-231.63%42.53%-15.29%
49
Neutral
$6.84B0.05-53.14%2.48%24.49%-3.26%
46
Neutral
$1.13B-66.09%32387.34%15.93%
42
Neutral
$164.55M-7.31%-25.21%25.06%
33
Underperform
$47.91M-121.97%11011.11%57.13%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
VTVT
vTv Therapeutics
14.56
-3.44
-19.11%
AMRN
Amarin
0.41
-0.45
-52.33%
CORT
Corcept Therapeutics
54.85
31.62
136.12%
GERN
Geron
1.67
-1.69
-50.30%
AXSM
Axsome Therapeutics
121.65
46.11
61.04%
XERS
Xeris Pharmaceuticals
4.56
2.33
104.48%

vTv Therapeutics Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
vTv Therapeutics Highlights Progress on Diabetes Treatment
Positive
Jan 13, 2025

vTv Therapeutics has updated their slide presentation to highlight their progress in developing cadisegliatin, a novel oral liver-selective glucokinase activator for Type 1 Diabetes. This development, still undergoing clinical trials and regulatory processes, aims to address the high unmet need for more effective glycemic control solutions, potentially providing investors and stakeholders with significant market opportunities.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.